GlobeNewswire·Nov 10, 2026, 7:32 AM ET

Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit

Clearmind Medicine Inc. (Nasdaq: CMND) is among invitees to the Frontiers of Mental Health and Recovery Summit in Washington D.C., convened by BrainFutures with support from the Steven & Alexandra Cohen Foundation.
Mary-Elizabeth Gifford, Chief of Global Impact, will participate in collaborative working sessions to accelerate system readiness for psychedelic therapies.
Gifford will discuss Clearmind's scalable treatment model using non-hallucinogenic neuroplastogens to potentially reduce the need for lengthy & costly supervised dosing.
The company will share insights on CMND-100, an investigational MEAI-based candidate for Alcohol Use Disorder, alongside updates from Phase II clinical trials at Yale School of Medicine & Johns Hopkins Medicine.
Gifford previously advocated for responsible patient access through existing primary care & VA resources during a September 2026 FDA hearing on psychedelic medicine.
CEO Adi Zuloff-Shani emphasized the necessity of collaboration across science, clinical research, policy, & healthcare to advance treatment approaches.
Keynote speakers for the summit include representatives from the FDA, SAMHSA, NIDA, States Strategies, Harvard Law School, & the Veterans Health Administration.
Clearmind holds a portfolio of nineteen patent families, including 32 granted patents, & intends to seek additional intellectual property protections.
The company's stock trades on Nasdaq under the symbol "CMND".